APAC Non-Invasive Prenatal Testing Market

APAC Non-Invasive Prenatal Testing Market Size (2022 to 2027)

The size of the Non-Invasive Prenatal Testing Market was valued at USD 0.47 Billion in 2022. It is further projected to be growing at a CAGR of 20.3% and worth USD 1.18 billion by 2027.

The high incidence of chromosomal abnormalities with increasing maternal age, a growing preference for non-invasive treatments over invasive methods, and a better reimbursement situation for NIPT are primarily driving the market's growth in the APAC region. In the future, emerging markets such as China India are likely to provide considerable growth possibilities for market competitors. The improved healthcare infrastructure, increasing public healthcare expenditure, the presence of a big target patient population, and expanding awareness and availability of modern technology contribute to these markets' rapid rise.

The rise in the incidence of chronic diseases such as cancer and diabetes has increased the patient pool, which has increased demand for biological medications to treat various chronic diseases, fueling the growth of the Non-Invasive Prenatal Testing market. In addition, changing lifestyles, dietary habits, and exposure to mutagenic chemicals threaten to produce spontaneous mutations in fetuses and expectant mothers, leading to an increase in genetic and congenital disorders. This factor is expected to fuel demand for the Asia Pacific non-invasive prenatal diagnostics market during the forecast period.

One of the market's main driving forces is the improvement of payment policies for ordinary and low-risk pregnancies. Furthermore, non-invasive prenatal tests' advantages over other prenatal tests, such as their non-invasive nature, higher accuracy, and shorter procedure time, are expected to propel the NIPT market forward during the forecast period. Several public health authorities in significant nations have begun to offer these tests directly or are planning to do so soon. As the population becomes more aware of these procedures, the adoption and revenue growth of the test market is predicted to accelerate.

However, lack of test accessibility, ethical issues, and rigorous government regulations are only a few factors that will limit the Non-Invasive Prenatal Testing market's growth. At the same time, decreased per capita healthcare spending and a lack of suitable test reimbursement policies are two other factors that could hamper the APAC non-invasive prenatal testing market's growth.

This research report on the Asia Pacific non-invasive prenatal testing market has been segmented and sub-segmented into the following categories.

By Instruments: 

• Ultrasound
• NGS
• PCR
• Microarray

By Method: 

• FCMB
• Cf-DNA

By Application: 

• Trisomy
• Microdeletion
• Genetics
• Rh Factor

By End User: 

• Hospitals
• Diagnostic Labs

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The Asia Pacific is expected to be the fastest-growing regional market throughout the forecast period. The presence of companies like BGI, a significant player in the Non-Invasive Prenatal Testing market (NIPT) market in China, is expected to move the market ahead. Growing healthcare infrastructure, more awareness programs and conferences, and major companies' more significant focus on expanding their presence in Asia are all driving market growth in Asia. In the future, the market will have a lot of space to grow. The high adoption rate of non-invasive prenatal testing in the APAC region, particularly in China, Australia, and New Zealand, is a prominent factor driving market expansion. In China, young maternal age and high-risk pregnancies are expected to be three times greater than in the United States, indicating a profitable market for non-invasive prenatal diagnostics in the Asia Pacific region.

KEY MARKET PLAYERS:

Companies playing a key role in the Asia Pacific non-invasive prenatal testing market profiled in this report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).